Potential Collaboration

A key to the success of AETIONOMY will be the quality and quantity of data from patients with Alzheimer’s and Parkinson’s disease that we can access.  AETIONOMY is being built on the datasets from the current collaborators and the publically available datasets.  However we know that whilst this is a good starting point there are a lot of high quality datasets that we cannot access.  The aim of AETIONOMY is to develop a comprehensive map of pathophysiological processes causing Alzheimer’s Disease and Parkinson’s Disease and these maps will be publically available to everyone.  These maps will form the basis of the new disease classification which we will be encouraging everyone to validate.  If you have datasets and are willing to collaborate then we would really like you to contact the AETIONOMY project office as we want this project to be as comprehensive as possible and a foundation for Alzheimer’s and Parkinson’s disease research and clinical practice for the biomedical community.

The structure and size of the project consortium and the proposed project activities have been formulated to ensure a cost effective approach to realising the project objectives. Care has been taken that all activities are well covered, and the amounts are realistically presented.

The following partners participate in the AETIONOMY project:

	UCB Pharma	Belgium
	Fraunhofer-Gesellschaft e.V.	Germany
	Erasmus Medical Center	Netherlands
	Universitaetsklinikum Bonn	Germany
	ICM- Institut du Cerveau et de la Moelle épinière	France
	Consorci Institut D´Investigacions Biomediques August Pi l Sunyer	Spain
	Leibniz Universitaet Hannover	Germany
	Pharmacoidea Ltd.	Hungary
	Luxembourg Centre for Systems Biology	Luxembourg
	Alzheimer Europe	Luxembourg
	Karolinska Institutet	Sweden
	Novartis	Switzerland
	Sanofi	France
	Boehringer Ingelheim	Germany
	Institut de Neurosciences des Systèmes	Marseille, France
	BARCELONABETA	Barcelona

AETIONOMY has 10 academic partners (of which 4 are clinical partners), 2 SMEs and 4 EFPIA partners. The 4 committed partners (UCB; Novartis, SARD & BI), have allocated resources  as well as a substantial financial support  of in-kind contribution over the  entire project. The AETIONOMY project is organised in 5 work packages. Work packages 1, 2, 4 and 5 have been pre-defined in the call text, so that only for WP3 were we free to chose a topic and title which is now called “clinical study”, as this reflects the nature of the clinical validation efforts.